NKTR Profile — Nektar Therapeutics
Nektar Therapeutics is a research-based biopharmaceutical company. Co.'s research and development pipeline of investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, Co. is studying several immuno-oncology drug candidates including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, Co. is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In virology, Co.'s programs include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. to test the combination of NKTR-255.
|
|
Free NKTR Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Hold (1.50 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Based on data provided by Zacks Investment Research via Quandl.com |